 |
 |
|
Rapid Responses to:
|
|
Electronic letters published:
![[Read Rapid Response]](/icons/misc/sectionDOWN.gif){kind=icon}
Bed-Side Biophysical-Semeiotic Evaluation of Thyroid Dysfunction in Cardiology.
|
|
|||
|
Sergio Stagnaro, Researcher in Biophysical Semeiotics Riva Trigoso (Genova) Italy Biophysical Semeiotics Research Laboratory
Send rapid response to journal:
dottsregio{at}semeioticabiofisica.it Sergio Stagnaro
|
Editors, in a 52-year-long clinical experience, Biophysical Semeiotics (See www.semeioticabiofisica.it), proved to be useful and reliable in both recognizing overt endocrine dysfunctions, and their relative early stages, i.e., Inherited Real Risk, based on microcirculatory remodelling, characterized by new born-pathological, type I, subtype b), aspecific, Endoarteriolar Blocking Devices (1-10). As a consequence, from clinical viewpoint, I agree completely with Authors’ conclusion. In addition, I’d like to underline firstly the importance of “clinical” assessing both insulinemia-insulinresistance and thyroid function in cardiology, not dependent of patient’s age (1, 2, 3, 4). In fact, even in western countries, doctors can not study glucose metabolism and thyroid function in a refined laboratory manner on very large scale, since these sophisticated investigations are really too expensive for our NHSs, if applied also to very numerous patients apparently health, although really involved by either Pre-Metabolic as well as Metabolic Syndrome with IGT, Prediabetes, undiagnosed type 2 diabetes mellitus, or hypothyroidism (3, 8). Secondly, all risk factors as well as thyroid dysfunction can brings about CHD exclusively in individuals involved, since birth, by CHD Inherited Real Risk, but not in all others patients with thyroid disorder. Fortunately Biophysical Semeiotics allows doctors to recognize early, rapidly, and precisely all these dangerous pathological conditions, that play a pivotal role also in Cardiology . Unfortunately, the scientific advances, particularly if really original, face great difficulty to be accepted, although farsighted Editors accept to post them(7-10). According to the greatest scientist Max Planck, “A new scientific truth does not triumph by convincing its opponents and making them see the light, but rather because its opponents eventually die, and a new generation grows up that is familiar with it. 1) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica: valutazione clinica del picco precoce della secrezione insulinica di base e dopo stimolazione tiroidea, surrenalica, con glucagone endogeno e dopo attivazione del sistema renina-angiotesina circolante e tessutale. Acta Med. Medit. 13, 99, 1997. 2) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica: la manovra di Ferrero-Marigo nella diagnosi clinica della iperinsulinemia-insulino resistenza. Acta Med. Medit. 13, 125,1997 3) Stagnaro Sergio, Stagnaro-Neri Marina. Introduzione alla Semeiotica Biofisica. Il Terreno oncologico”. Travel Factory SRL., Roma, 2004. http://www.travelfactory.it/semeiotica_biofisica.htm 4) Stagnaro S., West PJ., Hu FB., Manson JE., Willett WC. Diet and Risk of Type 2 Diabetes. N Engl J Med. 2002 Jan 24;346(4):297-298. [Medline] 5) Stagnaro Sergio. Role of Coronary Endoarterial Blocking Devices in Myocardial Preconditioning - c007i. Lecture, V Virtual International Congress of Cardiology. http://www.fac.org.ar/qcvc/llave/c007i/stagnaros.php 6) Stagnaro Sergio. Reale Rischio Congenito di CAD: Nosografia e Terapia. www.fce.it 22 maggio 2008 http://www.fcenews.it/index.php?option=com_content&task=view&id=1390&Itemid=47 7) Stagnaro Sergio. Bedside recognizing Inherited CAD Real Risk. www.natura.com, 21 May, 2008. http://network.nature.com/forums/pmgs/1587?page=1#reply-4262 8) Stagnaro Sergio. Epidemiological evidence for the non-random clustering of the components of the metabolic syndrome: multicentre study of the Mediterranean Group for the Study of Diabetes. Eur J Clin Nutr. 2007 Feb 7;[PubMed]. 9) Stagnaro Sergio. Newborn-pathological Endoarteriolar Blocking Devices in Diabetic and Dislipidaemic Constitution and Diabetes Primary Prevention. The Lancet. March 06 2007. http://www.thelancet.com/journals/lancet/article/PIIS0140673607603316/comments?totalcomments=1 10) Stagnaro Sergio. New bedside way in Reducing mortality in diabetic men and women. Ann. Int. Med. 21, June 2007 http://www.annals.org/cgi/eletters/0000605-200708070-00167v1 Conflict of Interest:None declared |
|||
